Key Highlights
- Shares of Relmada Therapeutics jumped approximately 31% during pre-market hours on Monday following two significant company announcements
- Phase 2 interim data for NDV-01 in bladder cancer revealed an impressive 76% complete response rate at 12 months
- Relmada successfully closed an oversubscribed private placement worth $160 million at a price of $4.75 per share
- The financing deal encompasses 29.47 million common shares plus pre-funded warrants for 4.21 million additional shares, set to close March 11
- Analyst sentiment remains bullish on RLMD with a Strong Buy rating and $10.25 average price target
The initial announcement centered on interim results from the company’s Phase 2 clinical study evaluating NDV-01 for treating high-risk non-muscle invasive bladder cancer (NMIBC). Data demonstrated a 12-month complete response rate reaching 76%, accompanied by a well-tolerated safety profile. Notably, the treatment achieved this same efficacy benchmark among BCG-unresponsive patients specifically.
Raj S. Pruthi, MD, serving as Relmada’s Chief Medical Officer of Oncology, characterized the findings as “meaningful clinical validation” for the development program.
Relmada Therapeutics, Inc., RLMD
Management indicated plans to move NDV-01 forward into a pivotal Phase 3 registrational study dubbed the RESCUE program, which will pursue two distinct regulatory pathways: one targeting BCG-unresponsive patients and another for adjuvant treatment in intermediate-risk cases. Initiation of the Phase 3 trial is anticipated around mid-2026.
Major Capital Infusion of $160 Million
In tandem with the clinical update, Relmada disclosed it had successfully priced an oversubscribed private investment in public equity (PIPE) transaction totaling $160 million.
The financing package consists of 29,474,569 common shares offered at $4.75 apiece, along with pre-funded warrants covering an additional 4,210,527 shares priced at $4.749 with a minimal $0.001 exercise price.
Jefferies, Leerink Partners, Piper Sandler, and Mizuho are serving as placement agents for the transaction. The closing date is scheduled for March 11, 2026, pending customary closing conditions.
Funds raised will be allocated toward working capital requirements and furthering the company’s research and development initiatives.
The agreement includes resale registration rights for investors. Relmada has committed to meeting SEC filing deadlines, with potential liquidated damages of 1.0% per 30-day delay period if timelines aren’t met, though these damages are subject to certain caps.
Share Price Performance
RLMD climbed 31.01% in pre-market trading Monday morning. The shares had already posted modest gains in Friday’s session.
For the year-to-date period, the stock remains down 7.87%. However, looking back over the trailing 12-month period reveals a remarkable gain of 1,536%.
Trading activity exploded following the announcements. Volume exceeded 7.9 million shares on Monday, dramatically outpacing the three-month average daily volume of approximately 570,000 shares.
This volume spike — representing more than 13 times the typical daily activity — demonstrates the significant investor interest generated by both announcements.
Wall Street analysts currently maintain a Strong Buy consensus rating on RLMD, supported by four Buy recommendations issued within the last three months.
The average analyst price target stands at $10.25, suggesting potential upside of approximately 130% from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
